Chikungunya is a viral infection transmitted by the Aedes aegypti and Aedes albopictus mosquitoes, which are widespread in tropical and subtropical regions. The disease is particularly prevalent in the Caribbean, Central and South America, parts of Africa and Asia. As international travel increases, so does the risk of exposure to the virus, making prevention and vaccination essential for travelers and populations living in high-risk areas.
What is Chikungunya?
Chikungunya is caused by a virus belonging to the alphavirus family. The name “Chikungunya” means “to curl up” in the Makonde language, due to the intense joint pain that often forces patients to bend over. This viral infection manifests itself through a combination of symptoms that can vary in intensity depending on the age and general state of health of the individual.
Mosquitoes carrying the virus are particularly active during the day, especially at sunrise and sunset, and breed in stagnant water. This means that protection against mosquito bites is essential, even outside swampy or wet areas.
Chikungunya symptoms
Symptoms usually appear 3 to 7 days after the infecting bite and may include:
- Sudden high fever, often accompanied by chills
- Severe joint pain, particularly in the wrists, knees and ankles
- Intense muscle pain and headaches
- Extreme fatigue, lasting up to several weeks
- Skin rashes on the body or face
- Occasional nausea and mild digestive disorders
In some people, especially adults and the elderly, joint pain can persist for several months, affecting mobility and quality of life. In rare cases, the virus can cause neurological or cardiac complications.
How is Chikungunya diagnosed?
Diagnosis is generally based on :
- Clinical evaluation: the doctor examines symptoms and travel history.
- Blood tests: to detect the virus or antibodies specific to Chikungunya.
- The exclusion of other infections: such as dengue or Zika, which present similar symptoms.
Early diagnosis is essential to manage symptoms and avoid complications.
Treatment and care
There is currently no specific antiviral treatment for Chikungunya. Management is based on symptom relief:
- Analgesics and anti-inflammatories to reduce pain and fever
- Rest and adequate hydration to support the immune system
- Monitor for unusual symptoms and consult a physician if necessary.
Severe cases are rare, but the disease can be very disabling, especially for people with chronic illnesses or the elderly.
Prevention: avoid mosquito bites
Chikungunya prevention is based on personal protection against mosquitoes:
- Apply effective DEET or icaridin-based repellents
- Wear long, light-colored clothing to limit skin exposure
- Sleep under a mosquito net, especially in areas where the virus is actively circulating.
- Eliminate stagnant water around homes and living areas
- Avoid visiting areas with high mosquito densities at peak activity times.
Even with these measures, the risk is not zero, which makes the IXCHIQ vaccine particularly interesting for travelers.
IXCHIQ vaccine: an effective solution against Chikungunya
IXCHIQ is the first vaccine approved in Canada to prevent Chikungunya. It is an effective way to reduce the risk of infection and severe symptoms.
Essential information about the vaccine
- Recommended audience: adults aged 18 to 64
- Cost: approximately $260 per dose
- Administration: single injection in specialized clinic
- Effective: protects against the virus and reduces the severity of symptoms
The vaccine is recommended for travellers to high-risk areas, as well as for people living in areas where the virus circulates regularly.
Tips for travelers
- Schedule a consultation with a travel health professional to assess the need for the vaccine.
- Get vaccinated in advance, as maximum protection requires a delay before exposure to the virus.
- Continue to use mosquito repellent measures, even after vaccination.
- Watch for the appearance of symptoms after returning from a trip, and consult a doctor promptly if necessary.
Why protect yourself against Chikungunya?
Chikungunya is generally not fatal, but it can cause persistent joint pain, fatigue and rare complications. Exposed travelers may find their stay affected, and people living in endemic areas may experience impacts on their daily lives. Thanks to the IXCHIQ vaccine and preventive measures, it is possible to significantly reduce the risks and travel or live more serenely.
Conclusion
Chikungunya is a serious viral disease, but one that can be prevented through a combination of prevention and vaccination. The IXCHIQ vaccine represents a major advance in protection against this viral infection. Whether you’re a traveler or a resident of a high-risk region, plan your protection in advance, consult a healthcare professional and adopt the preventive measures you need to enjoy your stay to the full and protect your health.
Visit the Health Canada website for more information: https: //www.canada.ca/fr/sante-publique/services/maladies/chikungunya.html
Book your travel health consultation with Priveo Santé now and leave with peace of mind, protected against Chikungunya and many other risks by calling us at 1-855-582-2246.
